Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail
Open Access
Abstract
A highly potent antitoxin for botulinum neurotoxin (BoNT) serotypes A and B has been developed that comprises three monoclonal antibodies (mAbs) targeting BoNT/A and three targeting BoNT/B. These oligoclonal antibody combinations neutralize toxin by simultaneously binding non-overlapping epitopes, thereby promoting rapid toxin clearance. All six mAbs use the same human Fc and framework and have been individually manufactured using the same expression platform and purification process. To minimize the time and labor required to produce the divalent antitoxin, we tested a co-expression and co-purification strategy for the three mAbs per serotype. The mAbs were expressed in CHO-K1 cells, and the media were optimized for co-expression in 10 L bioreactors. Chromatographic co-purification consisted of Protein A capture, followed by strong anion exchange chromatography in flow-through mode and cation-exchange chromatography in bind-elute mode. Co-expression experiments demonstrated that expression of the three anti-BoNT/A antibodies remained within approximately ±30% of the optimal equimolar ratio, whereas the anti-BoNT/B antibodies showed greater variability. Downstream purification steps achieved recoveries greater than 95% per chromatographic step, resulting in overall process yields of approximately 63–75%. This strategy provided sufficient purity of all six mAbs while largely preserving their relative ratios. These results demonstrate the feasibility of producing oligoclonal antitoxin antibodies using co-expression and shared purification strategies. Such approaches may simplify the manufacturing of antibody cocktails while maintaining product quality and biological activity.Keywords
Funding Information
- U.S. Department of War (W911SR22D0009)
- Defense Threat Reduction Agency (W15QKN-16-9-1002)
This publication has 33 references indexed in Scilit:
- Single‐Batch Expression of an Experimental Recombinant Snakebite Antivenom Based on an Oligoclonal Mixture of Human Monoclonal AntibodiesBiotechnology Journal, 2024
- It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody CombinationsJournal of Pharmaceutical Sciences, 2022
- Improving mAb capture productivity on batch and continuous downstream processing using nanofiber PrismA adsorbentsJournal of Biotechnology, 2021
- Process and operations strategies to enable global access to antibody therapiesBiotechnology Progress, 2021
- Recent successes in therapeutics for Ebola virus disease: no time for complacencyThe Lancet Infectious Diseases, 2020
- Recombinant antibody mixtures: Production strategies and cost considerationsArchives of Biochemistry and Biophysics, 2012
- Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same proteinAnalytical Biochemistry, 2012
- Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single proteinAnalytical Biochemistry, 2011
- Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnologyNew Biotechnology, 2011
- Recent advances in large-scale production of monoclonal antibodies and related proteinsTrends in Biotechnology, 2010